Status:
COMPLETED
A Study of Saxagliptin in Subjects With Type 2 Diabetes Who Have Inadequate Blood Sugar Control With Sulfonylureas
Lead Sponsor:
AstraZeneca
Conditions:
Diabetes
Eligibility:
All Genders
18-77 years
Phase:
PHASE3
Brief Summary
The purpose of this trial is to understand if adding saxagliptin to a sulfonylurea is safe and works better than increasing the amount of sulfonylurea a patient takes
Detailed Description
All subjects will participate in a lead-in period, and qualifying subjects will continue into a short-term randomized treatment period. Subjects who complete the short-term period will be eligible to ...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Type 2 Diabetes.
- Treated with a sulfonylurea for at least 2 months.
- Inadequate blood sugar control.
- Are not on any other medications to lower blood sugar.
- No major heart, liver or kidney problems.
- Women not pregnant or breast feeding.
Exclusion
Key Trial Info
Start Date :
April 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2008
Estimated Enrollment :
768 Patients enrolled
Trial Details
Trial ID
NCT00313313
Start Date
April 1 2006
End Date
September 1 2008
Last Update
May 4 2015
Active Locations (115)
Enter a location and click search to find clinical trials sorted by distance.
1
Reserach Solutions, Llc
Jonesboro, Arkansas, United States, 72401
2
Searcy Medical Center
Searcy, Arkansas, United States, 72143
3
Stewart Medical Group
Alhambra, California, United States, 91801
4
Southland Clinical Research Center, Inc.
Fountain Valley, California, United States, 92708